Skip to main content
SpringerLink
Log in

Funding a Clinical Trial

The Perspective of a Medicines Funder

  • Commentary
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Simoens S. Trastuzumab in early-stage breast cancer: the question of treatment timing. Pharmacoeconomics 2008; 26 (10): 807–9

    Article  PubMed  Google Scholar 

  2. A Coghlan (2007) ArticleTitleCheap, safe drug kills most cancers New Scientist 2857 13 Occurrence Handle10.1016/S0262-4079(07)60130-4

    Article  Google Scholar 

  3. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007 Jan; 11 (1): 37–51

    Article  PubMed  CAS  Google Scholar 

  4. Davis BR, Piller LB, Cutler JA, et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 2006 May 9; 113 (18): http://circ.ahajournals.org/cgi/reprint/113/18/22012008 Aug 28]

    Article  PubMed  CAS  Google Scholar 

  5. Steinbrook R. The price of sight: ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355: 1409–12

    Article  PubMed  CAS  Google Scholar 

  6. Pollack A. US to hold head-to-head trial of 2 Genentech drugs to treat eye ailment. NY Times 2006 Oct 6[online]. Available from URL: http://www.nytimes.com/2006/10/06/business/06drug.html [Accessed 2008 Aug 28]

  7. Triggle N. Lucentis: an NHS dilemma. BBC News 2008 Aug 27[online]. Available from URL: http://news.bbc.co.uk/2/hi/health/7582740.stm [Accessed 2008 Aug 28]

  8. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 Apr 8; 350 (15): 1495–504

    Article  PubMed  CAS  Google Scholar 

  9. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003 May 31; 326 (7400):1167–70[online]. Available from URL: http://www.bmj.com/cgi/content/full/326/7400/1167

    Article  PubMed  Google Scholar 

  10. Montori VM, Jaeschke R, Schünemann HJ, et al. Users’ guide to detecting misleading claims in clinical research reports. BMJ 2004 Nov 6; 329 (7474): 1093–6[online]. Available from URL: http://www.bmj.com/cgi/content/full/329/7474/1093

    Article  PubMed  Google Scholar 

  11. Smith I, Procter M, Gelber RD, et al. 2 year follow up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29–36

    Article  PubMed  CAS  Google Scholar 

  12. Bruzzi P. Non-drug industry funded research. BMJ 2008 Jan 5; 336 (7634): 1–2

    Article  PubMed  Google Scholar 

  13. McCartney M. Leaping to conclusions. BMJ 2008 May 31; 336 (7655): 1213–4[online]. Available from http://www.bmj.com/cgi/content/full/336/7655/1213

    Article  PubMed  Google Scholar 

  14. Pearce N. Adverse reactions: the fenoterol story. Auckland: Auckland University Press, 2007

    Google Scholar 

  15. Shirtcliffe P, Holt S, Crane J, et al. Towards the optimal use of inhaled corticosteroid therapy in adult asthma. N Z Med J 2001 Jun 8; 114 (1133): 263–5

    PubMed  CAS  Google Scholar 

  16. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006 Feb 23; 354 (8): 809–20

    Article  PubMed  CAS  Google Scholar 

  17. Ratain MJ, Cohen EE. The value meal: how to save $1700 per month or more on lapatinib. J Clin Oncol 2007 Aug 10; 25 (23): 3397–8[online]. Available from URL: http://jco.ascopubs.org/cgi/content/full/25/23/3397

    Article  PubMed  Google Scholar 

  18. Gazarian M, Kelly M, McPhee JR, et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006 Nov 20; 185 (10): 544–8[online]. Available from URL: http://www.mja.com.au/public/issues/185_10_201106/gaz10250_fm.html28]

    PubMed  Google Scholar 

  19. McPherson KM, Harwood M, McNaughton HK. Ethnicity, equity, and quality: lessons from New Zealand. BMJ 2003 Aug 23; 327 (7412): 443–4

    Article  PubMed  CAS  Google Scholar 

  20. Courtney C, Farrell D, Gray R, et al. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004 Jun 26; 363 (9427): 105–15

    Google Scholar 

  21. Godlee F. Doctors and the drug industry. BMJ 2008; 336 (7634)[online]. Available from URL: http://www.bmj.com/cgi/content/full/336/7634/0

  22. Chalmers I. Addressing uncertainties about the effects of treatments offered to NHS patients: whose responsibility? J R Soc Med 2007 Oct; 100 (10): 440–1

    Article  PubMed  Google Scholar 

  23. Metcalfe S, Evans J, Priest G. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer. N Z Med J 2007 15 Jun; 120 (1256)[online]. Available from URL: http://www.nzma.org.nz/journal/120-1256/2593

  24. Brougham M. Medicines funding: value for money is nothing new [letter]. BMJ 2007 Aug 18; 335 (7615): http://www.bmj.com/cgi/reprint/335/7615/318-a

  25. Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008 Feb 2; 336 (7638): 251–4[online]. Available from URL: http://www.bmj.com/cgi/content/full/336/7638/251

    Article  PubMed  Google Scholar 

  26. Berenson A. Cancer drugs offer hope, but at a huge expense. NY Times 2005 Jul 12[online]. Available from URL: http://www.nytimes.com/2005/07/12/business/12cancer.html?._r=2&oref=slogin&oref=slogin [Accessed 2008 Aug 28]

  27. Morrill D. Genentech bumps $40 drug with $2000 version: US senator chides Genentech plan. Contra Costa Times 2007 Nov 29[online]. Available from URL: http://www.pnhp.org/news/2007/november/genentech_bumps_40_.php [Accessed 2008 Aug 28]

  28. Kolata G, Pollack A. Costly cancer drug offers hope, but also a dilemma. NY Times 2008 Jul 6[online]. Available from URL: http://www.nytimes.com/2008/07/06/health/06avastin.html [Accessed 2008 Aug 28]

Download references

Acknowledgements

PHARMAC is part-funding the SOLD trial.

Author information

Authors and Affiliations

  1. Pharmaceutical Management Agency (PHARMAC), Level 9, Cigna House, 40 Mercer Street, Wellington, New Zealand

    Peter Alsop, Scott Metcalfe & Jackie Evans

Authors
  1. Peter Alsop
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott Metcalfe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jackie Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Alsop.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alsop, P., Metcalfe, S. & Evans, J. Funding a Clinical Trial. Pharmacoeconomics 26, 811–814 (2008). https://doi.org/10.2165/00019053-200826100-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200826100-00002

Keywords

Search

Navigation